Anti-apoptotic potential of rosuvastatin pretreatment in murine model of cardiomyopathy
Authors:
- Rahila Ahmad PathanRPRahila Ahmad Pathan
- Vinay KumarVKVinay Kumar
- Saleem JavedSJSaleem Javed
- Uma BhandariUBUma Bhandari
- 1 July 2011
- journal article
- research article
- Published by Elsevier in International Journal of Cardiology
- Vol. 150 (2) , 193-200
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Ethical authorship and publishingInternational Journal of Cardiology, 2009
- Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialThe Lancet, 2008
- Effect of Rosuvastatin on Methionine‐Induced Hyperhomocysteinaemia and Haematological Changes in RatsBasic & Clinical Pharmacology & Toxicology, 2008
- Rosuvastatin in Older Patients with Systolic Heart FailureNew England Journal of Medicine, 2007
- Protective effect ofSpirulina against doxorubicin-induced cardiotoxicityPhytotherapy Research, 2005
- Protective effect of Centella asiatica on antioxidant tissue defense system against adriamycin induced cardiomyopathy in ratsLife Sciences, 2004
- Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicityToxicology and Applied Pharmacology, 2004
- Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)The American Journal of Cardiology, 2003
- Modification of doxorubicin-induced cardiotoxicityEuropean Journal of Cancer, 2001
- Doxorubicin‐induced cardiomyopathy treated with carvedilolClinical Cardiology, 1998